PipelineReview.com - CAR T-Cells & NK Cells

Show Cart

CAR T-Cells & NK Cells

Results 1 - 4 of 4

Oct 2019 Flat-Rate Subscription to La Merie Publishing Reports

Sep 2016 Report package: T-Cell Immunotherapy by bispecific antibodies and CAR & TCR engineered T-cells

(Discount: 33.33%)

Aug 2016 TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

Mar 2015 Engineered TCR and CAR Immunotherapeutics 2015

(Discount: 20.00%)

Shopping cart

Cart empty

Latest report

Competitor Analysis: Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More

Featured Products

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Bispecific Antibodies for Immuno-Oncology & Other Diseases

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Latest Target Pipeline

CD38-Targeted Antibody & Cell Therapy

Shopping cart

Cart empty

Latest report

Competitor Analysis: Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More

Featured Products

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Bispecific Antibodies for Immuno-Oncology & Other Diseases

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Latest Target Pipeline

CD38-Targeted Antibody & Cell Therapy

La Merie Biologics

FREE Weekly News Bulletin

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing